The Therapeutic Effects of Bone Marrow-Derived Mesenchymal Stem Cells and Simvastatin in a Rat Model of Liver Fibrosis

Cell Biochemistry and Biophysics

Volumn 68, Issue 1, 2014, Pages 111-125

  Motawi, Tarek M K ^a   Atta, Hazem M ^a   Sadik, Nermin A H ^a   Azzam, May ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Liver fibrosis; Mesenchymal stem cells; Rats; Simvastatin

Indexed keywords

ANIMALIA; RATTUS;

ANTILIPEMIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 2; ENDOGLIN PROTEIN, RAT; SIGNAL PEPTIDE; SIMVASTATIN; TESTIS DETERMINING FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL; ARTICLE; BONE MARROW CELL; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER CIRRHOSIS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; RAT; SEVERITY OF ILLNESS INDEX; WISTAR RAT;

ANIMALS; BONE MARROW CELLS; COLLAGEN TYPE I; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HYPOLIPIDEMIC AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER CIRRHOSIS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; SEX-DETERMINING REGION Y PROTEIN; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84891628507     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9698-1     Document Type: Article

References (73)

1. Friedman, S. L. (2003). Liver fibrosis-From bench to bedside. Journal of hepatology, 38(Suppl 1), S38-S53.
2. Gines, P., Cardenas, A., Arroyo, V., & Rodes, J. (2004). Management of cirrhosis and ascites. New England Journal of Medicine, 350, 1646-1654.
3. Bataller, R., & Brenner, D. A. (2005). Liver fibrosis. The Journal of Clinical Investigation, 115, 209-218.
4. Hemmann, S., Graf, J., Roderfeld, M., & Roeb, E. (2007). Expression of MMPs and TIMPs in liver fibrosis-A systematic review with special emphasis on anti-fibrotic strategies. Journal of Hepatology, 46, 955-975.
5. Consolo, M., Amoroso, A., Spandidos, D., & Mazzarino, M. (2009). Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). International Journal of Molecular Medicine, 24, 143-152.
6. Kessenbrock, K., Plaks, V., & Werb, Z. (2010). Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 141, 52-67.
7. Freeman, R. B., Jr., Steffick, D. E., Guidinger, M. K., Farmer, D. G., Berg, C. L., & Merion, R. M. (2008). Liver and intestine transplantation in the United States, 1997-2006. American Journal of Transplantation, 8, 958-976.
8. Piersma, A. H., Brockbank, K. G., Ploemacher, R. E., van Vliet, E., Brakel-van Peer, K. M., & Visser, P. J. (1985). Characterization of fibroblastic stromal cells from murine bone marrow. Experimental Hematology, 13, 237-243.
9. Owen, M., & Friedenstein, A. J. (2007). Stromal stem cells: Marrow-derived osteogenic precursors. In Ciba Foundation Symposium 136-Cell and Molecular Biology of Vertebrate Hard Tissues. Chichester: Wiley.
10. Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 418, 41-49.
11. Assmus, B., Honold, J., Schachinger, V., Britten, M. B., Fischer-Rasokat, U., Lehmann, R., et al. (2006). Transcoronary transplantation of progenitor cells after myocardial infarction. New England Journal of Medicine, 355, 1222-1232.
12. Bang, O. Y., Lee, J. S., Lee, P. H., & Lee, G. (2005). Autologous mesenchymal stem cell transplantation in stroke patients. Annals of Neurology, 57, 874-882.
13. Zhang, Z. X., Zhang, Y. Z., Guan, L. X., Zhou, Y. J., Zhao, X. X., Cai, Y. H., et al. (2007). Autotransplantation of purified mesenchymal stem cells in a patient with acute myocardial infarction: A case study. Journal of Stem Cells, 2, 185-189.
14. Zhang, Z. X., Guan, L. X., Zhang, K., Zhang, Q., & Dai, L. J. (2008). A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy, 10, 134-139.
15. Schwartz, R. E., Reyes, M., Koodie, L., Jiang, Y., Blackstad, M., Lund, T., et al. (2002). Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. The Journal of Clinical Investigation, 109, 1291-1302.
16. Lee, K. D., Kuo, T. K., Whang-Peng, J., Chung, Y. F., Lin, C. T., Chou, S. H., et al. (2004). In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology, 40, 1275-1284.
17. Fang, B., Shi, M., Liao, L., Yang, S., Liu, Y., & Zhao, R. C. (2004). Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation, 78, 83-88.
18. Oxana Lukivskaya, M. K., Dudzik, D., Borzym-Kluczyk, M., Lis, R., Buko, V., & Zwierz, K. (2007). Effects of statins on liver fibrosis reversibility and activities of lysosomal exoglycosidases. E&C Hepatology, 3, 14-17.
19. Jasinska, M., Owczarek, J., & Orszulak-Michalak, D. (2007). Statins: A new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacological Reports, 59, 483-499.
20. Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006). Statins and cancer risk: A meta-analysis. Journal of the American Medical Association, 295, 74-80.
21. Poynter, J. N., Gruber, S. B., Higgins, P. D., Almog, R., Bonner, J. D., Rennert, H. S., et al. (2005). Statins and the risk of colorectal cancer. New England Journal of Medicine, 352, 2184-2192.
22. Liberopoulos, E. N., Athyros, V. G., Elisaf, M. S., & Mikhailidis, D. P. (2006). Statins for non-alcoholic fatty liver disease: A new indication? Alimentary Pharmacology & Therapeutics, 24, 698-699.
23. Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004). Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology, 126, 1287-1292.
24. Furberg, C. D. (1999). Natural statins and stroke risk. Circulation, 99, 185-188.
25. Alhadlaq, A., & Mao, J. J. (2004). Mesenchymal stem cells: Isolation and therapeutics. Stem Cells and Development, 13, 436-448.
26. Moriya, K., Yoshikawa, M., Ouji, Y., Saito, K., Nishiofuku, M., Matsuda, R., et al. (2008). Embryonic stem cells reduce liver fibrosis in CCl4-treated mice. International Journal of Experimental Pathology, 89, 401-409.
27. Zhao, D. C., Lei, J. X., Chen, R., Yu, W. H., Zhang, X. M., Li, S. N., et al. (2005). Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World Journal of Gastroenterology, 11, 3431-3440.
28. Karmen, A. (1955). A note on the spectrometric assay of glutamic-oxalacetic transaminase in human blood serum. The Journal of Clinical Investigation, 34, 131-133.
29. Reitman, S., & Frankel, S. (1957). A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. American Journal of Clinical Pathology, 28, 56-63.
30. Kind, P. R., & King, E. J. (1954). Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. Journal of Clinical Pathology, 7, 322-326.
31. Belfield, A., & Goldberg, D. M. (1971). Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme, 12, 561-573.
32. Tietz, N. W. (1995). Clinical guide to laboratory tests (pp. 518-522). Philadelphia, PA: WB Saunders Company.
33. Doumas, B. T., Watson, W. A., & Biggs, H. G. (1971). Albumin standards and the measurement of serum albumin with bromocresol green. Clinica Chimica Acta; International Journal of Clinical Chemistry, 31, 87-96.
34. Wang, H. S., Hung, S. C., Peng, S. T., Huang, C. C., Wei, H. M., Guo, Y. J., et al. (2004). Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells, 22, 1330-1337.
35. Wu, G. D., Tuan, T. L., Bowdish, M. E., Jin, Y. S., Starnes, V. A., Cramer, D. V., et al. (2003). Evidence for recipient derived fibroblast recruitment and activation during the development of chronic cardiac allograft rejection. Transplantation, 76, 609-614.
36. Abdel Aziz, M. T., Atta, H. M., Mahfouz, S., Fouad, H. H., Roshdy, N. K., Ahmed, H. H., et al. (2007). Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clinical Biochemistry, 40, 893-899.
37. Scheuer, P. J., Standish, R. A., & Dhillon, A. P. (2002). Scoring of chronic hepatitis. Clinics in Liver Disease, 6, 335-347, v-vi.
38. Bedossa, P., Poynard, T., & The METAVIR Cooperative Study Group. (1996). An algorithm for the grading of activity in chronic hepatitis C. Hepatology, 24, 289-293.
39. Bruckner, J. V., Ramanathan, R., Lee, K. M., & Muralidhara, S. (2002). Mechanisms of circadian rhythmicity of carbon tetrachloride hepatotoxicity. Journal of Pharmacology and Experimental Therapeutics, 300, 273-281.
40. Roy-Chaudhury, P., Simpson, J. G., & Power, D. A. (1997). Endoglin, a transforming growth factor-beta-binding protein, is upregulated in chronic progressive renal disease. Experimental Nephrology, 5, 55-60.
41. Garcia-Monzon, C., Sanchez-Madrid, F., Garcia-Buey, L., Garcia-Arroyo, A., Garcia-Sanchez, A., & Moreno-Otero, R. (1995). Vascular adhesion molecule expression in viral chronic hepatitis: Evidence of neoangiogenesis in portal tracts. Gastroenterology, 108, 231-241.
42. Cheifetz, S., Bellon, T., Cales, C., Vera, S., Bernabeu, C., Massague, J., et al. (1992). Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. The Journal of Biological Chemistry, 267, 19027-19030.
43. Lastres, P., Letamendia, A., Zhang, H., Rius, C., Almendro, N., Raab, U., et al. (1996). Endoglin modulates cellular responses to TGF-beta 1. Journal of Cell Biology, 133, 1109-1121.
44. Wiercinska, E., Wickert, L., Denecke, B., Said, H. M., Hamzavi, J., Gressner, A. M., et al. (2006). Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells. Hepatology, 43, 1032-1041.
45. di Bonzo, L. V., Ferrero, I., Cravanzola, C., Mareschi, K., Rustichell, D., Novo, E., et al. (2008). Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: Engraftment and hepatocyte differentiation versus profibrogenic potential. Gut, 57, 223-231.
46. Wynn, T. A. (2008). Cellular and molecular mechanisms of fibrosis. The Journal of Pathology, 214, 199-210.
47. Xu, X., Xu, Z., Xu, Y., & Cui, G. (2005). Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats. Coronary Artery Disease, 16, 245-255.
48. Parekkadan, B., van Poll, D., Suganuma, K., Carter, E. A., Berthiaume, F., Tilles, A. W., et al. (2007). Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE, 2, e941.
49. Dai, L. J., Li, H. Y., Guan, L. X., Ritchie, G., & Zhou, J. X. (2009). The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Research, 2, 16-25.
50. Kanazawa, Y., & Verma, I. M. (2003). Little evidence of bone marrow-derived hepatocytes in the replacement of injured liver. Proceedings of the National Academy of Sciences of the United States of America, 100(Suppl 1), 11850-11853.
51. Kinnaird, T., Stabile, E., Burnett, M. S., Shou, M., Lee, C. W., Barr, S., et al. (2004). Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation, 109, 1543-1549.
52. Silva, G. V., Litovsky, S., Assad, J. A., Sousa, A. L., Martin, B. J., Vela, D., et al. (2005). Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation, 111, 150-156.
53. Matsuda-Hashii, Y., Takai, K., Ohta, H., Fujisaki, H., Tokimasa, S., Osugi, Y., et al. (2004). Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor. Experimental Hematology, 32, 955-961.
54. Ueki, T., Kaneda, Y., Tsutsui, H., Nakanishi, K., Sawa, Y., Morishita, R., et al. (1999). Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nature Medicine, 5, 226-230.
55. Li, Y., Chen, J., Chen, X. G., Wang, L., Gautam, S. C., Xu, Y. X., et al. (2002). Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery. Neurology, 59, 514-523.
56. Trim, N., Morgan, S., Evans, M., Issa, R., Fine, D., Afford, S., et al. (2000). Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. The American Journal of Pathology, 156, 1235-1243.
57. Chen, X., Li, Y., Wang, L., Katakowski, M., Zhang, L., Chen, J., et al. (2002). Ischemic rat brain extracts induce human marrow stromal cell growth factor production. Neuropathology: Official Journal of the Japanese Society of Neuropathology, 22, 275-279.
58. Aiuti, A., Webb, I. J., Bleul, C., Springer, T., & Gutierrez-Ramos, J. C. (1997). The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. The Journal of Experimental Medicine, 185, 111-120.
59. Asumda, F. Z., & Chase, P. B. (2011). Age-related changes in rat bone-marrow mesenchymal stem cell plasticity. BMC Cell Biology, 12, 44.
60. Rombouts, K., Kisanga, E., Hellemans, K., Wielant, A., Schuppan, D., & Geerts, A. (2003). Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. Journal of Hepatology, 38, 564-572.
61. Rosenbloom, J., Saitta, B., Gaidarova, S., Sandorfi, N., Rosenbloom, J. C., Abrams, W. R., et al. (2000). Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I. Arthritis and Rheumatism, 43, 1624-1632.
62. Goldstein, J. L., & Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature, 343, 425-430.
63. Holstein, S. A., Wohlford-Lenane, C. L., & Hohl, R. J. (2002). Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. The Journal of Biological Chemistry, 277, 10678-10682.
64. Louneva, N., Huaman, G., Fertala, J., & Jimenez, S. A. (2006). Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis and Rheumatism, 54, 1298-1308.
65. Laufs, U., & Liao, J. K. (1998). Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. The Journal of Biological Chemistry, 273, 24266-24271.
66. Rikitake, Y., & Liao, J. K. (2005). Rho GTPases, statins, and nitric oxide. Circulation Research, 97(12), 1232-1235.
67. Jeong, W. I., Do, S. H., Jeong, D. H., Hong, I. H., Park, J. K., Ran, K. M., et al. (2006). Kinetics of MMP-1 and MMP-3 produced by mast cells and macrophages in liver fibrogenesis of rat. Anticancer Research, 26, 3517-3526.
68. Tan, A., Levrey, H., Dahm, C., Polunovsky, V. A., Rubins, J., & Bitterman, P. B. (1999). Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders. American Journal of Respiratory and Critical Care Medicine, 159, 220-227.
69. Ritzel, U., Leonhardt, U., Nather, M., Schafer, G., Armstrong, V. W., & Ramadori, G. (2002). Simvastatin in primary biliary cirrhosis: Effects on serum lipids and distinct disease markers. Journal of Hepatology, 36, 454-458.
70. Lewis, J. H., Mortensen, M. E., Zweig, S., Fusco, M. J., Medoff, J. R., & Belder, R. (2007). Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology, 46, 1453-1463.
71. Dale, K. M., White, C. M., Henyan, N. N., Kluger, J., & Coleman, C. I. (2007). Impact of statin dosing intensity on transaminase and creatine kinase. The American Journal of Medicine, 120, 706-712.
72. Chalasani, N. (2005). Statins and hepatotoxicity: Focus on patients with fatty liver. Hepatology, 41, 690-695.
73. Riley, P., Sudarshi, D., Johal, M., Benedict, A., Panteli, J., Crook, M., et al. (2008). Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: A retrospective study. International Journal of Clinical Practice, 62, 374-381.